Compare Gilead Sciences, Inc. (GILD) vs Kraft Heinz Co (KHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Kraft Heinz Co — how do they compare? Gilead Sciences, Inc. trades at $136.36 (market cap $163.51B), while Kraft Heinz Co trades at $26.19 (market cap $30.18B). The key difference: Gilead Sciences, Inc. is far larger — about 5.4× Kraft Heinz Co's market cap, and Kraft Heinz Co pays the higher dividend (6.29%). Which is the better fit depends on your goals.
| GILD | KHC | |
|---|---|---|
Market Cap | $163.51B | $30.18B |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $28.94 |
52-Week Low | $108.22 | $21.21 |
Enterprise Value | $178.05B | $47.22B |
Dividend Yield | 2.49% | 6.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Kraft Heinz (KHC) trades at $26.165, up 4.33% over the past session, with a bullish technical signal from moving averages. The stock shows mixed fundamentals with a negative net income margin of -23.05% in 2025 but has beaten EPS estimates for three consecutive quarters. Recent news highlights a global restructuring to accelerate growth and a $0.40 dividend payment scheduled for June 2026.
The outlook is cautious due to profitability challenges, though valuation metrics like P/B of 0.72 suggest potential undervaluation. Risks include execution of the new operating model and competitive pressures. Analyst consensus is predominantly Hold with a price target of $23.20, indicating limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →
